Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation

Results of GNS Healthcare study of the PPMI data set published in the Lancet Neurology

Learn more about the discovery of genetic and molecular markers of faster motor progression of Parkinson’s Disease (PD) patients, the LINGO2 gene together with a second genetic variant, along with demographic factors. The discovery was powered by patient data from the Parkinson’s Progression Markers Initiative sponsored by the Michael J. Fox Foundation for Parkinson’s Research. The study used the GNS causal machine learning and simulation platform, REFS™ (Reverse Engineering and Forward Simulation) and with more accurate predictors of rates of progression, there is the potential to remove uncertainties from drug development and patient response, reduce the number of clinical trial enrollees required by as much as twenty percent, and speed up the development of effective new drugs.



GNS  is leading the way, partnering with major names in the healthcare industry to provide value-based solutions such as:

  • Subpopulation Analysis
  • Disease Mechanisms of Action
  • Target Discovery
  • Value-based Drug Models
  • Intervention Optimization